This invention is related to the field of therapeutic delivery systems, and methods for improving the delivery, stability and efficacy of protein therapeutics.
Citation or identification of any reference herein, or any section of this application shall not be construed as an admission that such reference is available as prior art to the present application. The disclosures of each of these publications in their entireties are hereby incorporated by reference in their entirety in this application, and shall be treated as if the entirety thereof forms a part of this application.
Once a rarely used subset of medical treatments, protein therapeutics have increased dramatically in number and frequency of use since the introduction of the first recombinant protein therapeutic, human insulin, 25 years ago. Protein therapeutics already have a significant role in almost every field of medicine, but this role is still only in its infancy. (Leader et al., 2008, Protein therapeutics: a summary and pharmacological classification Nature Reviews Drug Discovery 7, 21-39).
Targeted monoclonal antibodies comprise a major form of therapeutic proteins. Targeting monoclonal antibodies to the tumor can result in the destruction of the tumor cells by antibody-dependent cellular cytotoxicity or complement-dependent cytotoxicity. Similarly, targeting cytokines or immunomodulatory molecules either by bispecific scFv or antibody—ligand fusion proteins to the tumor modulates the immune response against the tumor. In addition, antibody-ligand fusion proteins can induce apoptosis to targeted cells as well as bystander cells by, for example, presenting FasL. A more direct approach to kill the targeted cell is the conjugation of cytotoxic drugs, toxins or radionucleotides to the monoclonal antibodies. The antibody-directed enzyme prodrug therapy (ADEPT) approach specifically aims at causing bystander effects by targeting enzymes to the tumor cell and delivering a prodrug that is converted to a chemotherapeutic by the targeted enzyme. (Schrama et al., 2006, Antibody targeted drugs as cancer therapeutics, Nature Reviews Drug Discovery 5, 147-159). Examples of monoclonal antibody therapeutics are shown in Table I. However, means to enhance their protease stability have not been provided, particularly for tumor-targeted antibodies.
Protease inhibitors together with protease sensitive therapeutics are provided. Therefore, the localized in vivo activity of protease-sensitive drugs will be increased. Likewise, the physical region of activity for a highly protease sensitive peptide agent will be generally limited to the region in which both the protease inhibitor and peptide are present at sufficient concentrations.
The polymeric protease activated protease inhibitors can be homo- or hetero-inhibitor polymers, and/or homo- or hetero-protease cleavage site polymers. Combination with the protease inhibitors with the protease sensitive therapeutic enhances the intact, active molecule local-regional or targeted cell or tissue concentration, peak concentration and/or duration of the therapeutic exposure, thereby increasing its therapeutic efficacy. The protease inhibitors are particularly useful for tumor-targeted therapies and for vaccines.
The present invention comprises systems, compositions, and methods for using protease inhibitors together with protease sensitive therapeutics. The protease inhibitors may be ionically bound the protease sensitive therapeutic, covalently bound (e.g., connected through a covalent bond), or unbound. The protease inhibitors include monomeric protease inhibitors, and polymeric inhibitors where the inhibitors are themselves protease activated, or the protease inhibitors may be activated or activated in some other way. The protease cleavage site may be for the same protease that the peptide inactivates, and thus, the protease activates its own inhibitor. The protease inhibitor may be of a competitive or non-competitive type. The protease cleavage site may also be for a protease other than for the protease inhibitor, thus deactivating another protease. Multiple protease inhibitor peptides may be used in-frame with multiple protease cleavage signals (polymeric protease activated protease inhibitors). The polymeric protease activated protease inhibitors can be homo- or hetero-inhibitor polymers, and/or homo- or hetero-protease cleavage site polymers.
Combination of a protease inhibitor with a protease sensitive therapeutic may enhance the intact, active molecule local-regional or targeted cell or tissue concentration, peak concentration and/or duration of the therapeutic exposure, thereby increasing its therapeutic efficacy.
The protease inhibitors are particularly useful for tumor-targeted therapies, which for example include the protease sensitive therapeutic.
The compositions comprising a protease inhibitor and protease-sensitive agent may be administered in traditional manner through oral, transcutaneous, transmucosal, intravenous, intramuscular, intraperitoneal, intrathecal manner, or in situ administration in a solid or liquid form, encapsulated in a polymer or liposome, or employing known administration technologies. On the other hand, the protease inhibitor and/or protease sensitive agent may be produced by a genetically engineered cell or colony of cells, such as prokaryotic cells, e.g., Salmonella, E. coli, or mycoplasma sp., or eukaryotic cells, such as autologous human cells in the case of a human therapy or diagnostic aid.
The present invention provides, according to various embodiments, improved protein therapeutics with increased circulation (enhanced pharmacokinetics), longer half-lives and decreased degradation. In a preferred embodiment, the protein therapeutic is an antitumor antibody.
Therapeutic proteins are typically inherently sensitive to extracellular proteases. Proteases may be classified by several different systems, for example, into six groups: serine proteases, threonine proteases, cysteine proteases, aspartate proteases, metalloproteases and glutamic acid proteases. Alternatively, proteases may be classified by the optimal pH in which they are active: acid proteases, neutral proteases, and basic proteases (or alkaline proteases). Many proteases are over-expressed within tumors (Edwards et al. (eds) 2008, The Cancer Degradome: Proteases and Cancer Biology, Springer, 926 pp.) including tissue plasminogen activator, activated protein C, factor Xa, granzyme (A, B, M), cathepsins (e.g., cathepsin B and S), thrombin, plasmin, urokinase, matrix metaloproteaes (types 1-26) membrane matrix metalloproteases (types 1-4), prostate specific antigens (PSA; kallikrein 3-related peptidase), kallikrein 2, elastin, trypsin, chymotrypsin.
A variety of protease assays are known to those skilled in the art. Many protease assays are commercially available, such as the QuantiCleave Fluorescent Protease Assay Kit, and QuantiCleave Protease Assay Kit II (Thermo/Fisher, Rockford, Ill.), Protease Assay Kit (G Biosciences, Maryland Heights, Mo.), PepTag Protease Assay (Promega, Madison, Wis.; 1993 Promega Notes Magazine 44: 2), Viral Protease Assay Kits (AnaSpec, Fremont, Calif.), Protease Assay Kit from Calbiochem (Calbiochem, San Diego, Calif.).
Standard laboratory techniques to measure protease activity, and thus the reduced activity of protease inhibitors, include densitometric, spectrophotometric, colorometric and fluorometric assays, sodium dodecyl sulfate (SDS) polyacrylamide gel electrophoresis (PAGE), two dimentional SDS-PAGE, high pressure liquid chromatography (HPLC) and mass spectroscopy (mass-spec). Examples of protases and their cleavage signals are shown in Table 2.
Protease cleavage sites are defined in the Merops database (Rawlings et al., 2010, MEROPS: The Peptidase Database, Nucleic Acids Res. 2010 (Database issue):D227-33. It will be understood to those skilled in the arts that many proteases do not have strict sequence recognition sites, but rather have sequence preferences and/or frequencies. The MEROPS site depicts the preferences with a weighted pictogram and a table which lists frequencies of occurrence within a cleavage sequence. The table a non-limiting list proteases of tumors, the MEROPS sequence specification, and a simplified representative of an amino acid one letter code recognition sequence (where X is any amino acid) and the cleavage signal is given by a downward arrow) is presented in Table 2.
The MEROPS database can be used to identify which proteases to inhibit, by analysis of a particular effector protein and the cleavage sites it contains. Comparison with the target tissue, eg Edwards et al. (eds) 2008, The Cancer Degradome: Proteases and Cancer Biology, Springer, 926 pp is also used to inform the choice. Alternatively, 2-dimentional gel electrophoresis and protein sequencing of radiolabled peptides incubated with the target tumor can be used to identify which aminoacids are being cleaved in a therapeutic protein, and therefore which protease inhibitors to use.
Protease inhibitors usable in accordance herewith are preferably based on known polypeptide inhibitors. The inhibitors include both synthetic peptides and naturally occurring, endogenous peptides. Classes of protease inhibitors include: cysteine protease inhibitors, serine protease inhibitors (serpins), trypsin inhibitors, Kunitz STI protease inhibitor, threonine protease inhibitors, aspartic protease inhibitors, metalloprotease inhibitors. Protease inhibitors can also be classified by mechanism of action as suicide inhibitors, transition state inhibitors, protein protease inhibitor (see serpins) and chelating agents. The protease inhibitors are typically protein or polypeptide inhibitors that are activated by protease cleavage, resulting in a time-released “depot” effect.
The C-terminal sequences may provide a free protease inhibitor. The cleavage site may be for the same protease that the peptide inactivates. Thus, the protease activates its own inhibitor. The protease cleavage site may also be for a protease other than for the protease inhibitor, thus deactivating another protease. Multiple protease inhibitor peptides may be used in-frame with multiple protease cleavage signals (polymeric protease activated protease inhibitors), where the inhibitors alternate with cleavage sites. The polymeric protease activated protease inhibitors can be homo- or hetero-inhibitor polymers (i.e., have inhibitors for the same or different proteases, respectively), and/or homo- or hetero-protease cleavage polymers (i.e., have the same or different protease cleavage sites). Examples of proteases upregulated within tumors include: tissue plasminogen activator, activated protein C, factor Xa, granzyme (A, B, M), cathepsin, thrombin, plasmin, urokinase, matrix metaloproteaes, prostate specific antigen (PSA) and kallikrein 2 (e.g., Edwards et al. (eds) 2008, The Cancer Degradome: Proteases and Cancer Biology, Springer, 926 pp.), as well as proteases of lysosomes and the gut.
Protease inhibitors have been reviewed by Laskowski and Kato, 1980, (Annual Review of Biochemistry 49: 593-626), expressly incorporated by reference herein. Serine proteases inhibitors, the largest group, include 1) bovine pancreatic trypsin inhibitor (Kunitz) family, 2) pancreatic secretory trypsin inhibitor (Kazal) family, 3) Streptomyces subtilisin inhibitor family, 4) soybean trypsin inhibitor (Kunitz) family, 5) soybean proteinase inhibitor (Bowman-Birk) family 6) potato I inhibitor family, 7) potato II inhibitor family, 8) Ascaris trypsin inhibitor family, and 9) others. Protease inhibitors have also been grouped within the MEROPS peptidase database (Rawlings et al., 2008 Nucleic Acids Res. 36 Database issue, D320-325).
Specific examples of protease inhibitors that may be expressed as complete proteins or peptide fragments corresponding to the active inhibitory site include but are not limited to aprotinin, cathepsin inhibitor peptide sc-3130, Niserria protease inhibitor, lympocyte protease inhibitor, maspin, matrix metalloprotease inhibitors, macroglobulins, antithrombin, equistatin, Bowman-Birk inhbitor family, ovomucoid, ovoinhibitor-proteinase inhibitors from avian serum, dog submandibular inhibitors, inter-a-trypsin inhibitors from mammalian serum, chelonianin from turtle egg white, soybean trypsin inhibitor (Kunitz), secretory trypsin inhibitors (Kazal) ai-proteinase inhibitor, Streptomyces subtilisin inhibitor, plasminostreptin, plasmin inhibitor, factor Xa inhibitor, coelenterate protease inhibitors, protease inhibitor anticoagulants, ixolaris, human Serpins (SerpinA1 (alpha 1-antitrypsin), SerpinA2, SerpinA3, SerpinA4, SerpinA5, SerpinA6, SerpinA7, SerpinA8, SerpinA9, SerpinA10, SerpinA11, SerpinA12, SerpinA13, SerpinB1, SerpinB2, SerpinB3, SerpinB4, SerpinB5, SerpinB6, SerpinB7, SerpinB8, SerpinC1 (antithrombin), SerpinD1, SerpinE1, SerpinE2, SerpinF1, SerpinF2, SerpinG1, SerpinNI1, SerpinNI2), cowpea trypsin inhibitor, onion trypsin inhibitor, alpha 1-antitrypsin, Ascaris trypsin and pepsin inhibitors, lipocalins, CI inhibiotor, plasminogen-activator inhibitor, collegenase inhibitor, Acp62F from Drosophila, bombina trypsin inhibitor, bombyx subtilisin inhibitor, von Willebrand factor, leukocyte secretory protease inhibitor. Short peptide inhibitors of protease are preferred. Many protease inhibitors have one or more disulfide bonds. Fusion to thioredoxin (trxA) is known to improve protease inhibitor activity (e.g., Furuki et al., 2007, Fukuoka University Science Reports 37: 37-44). Fusion to glutathione-S transferase (GST) and co-expression with disulfide bond isomerase (DsbA) or nusA (Harrison 2000, Expression of soluble heterologous proteins via fusion with NusA protein. inNovations 11: 4-7) are also known to improve solubility. Examples of the peptide sequences of short peptide inhibitors is shown in Table 3.
Leader et al., 2008 (Nature Reviews Drug Discovery 7: 21-39, incorporated by reference in its entirety) divided protein therapeutics in to functional categories:
Group I: protein therapeutics with enzymatic or regulatory activity
Group II: protein therapeutics with special targeting activity
Group III: protein vaccines
Group IV: protein diagnostics.
Although other protein therapeutics previously dominated and have had well-established production protocols (e.g., Smales, C M and James, D. C (eds) 2005, Therapeutic Proteins: Methods and Protocols, Human Press), antibody therapeutics have been the most actively developed over the past 10 years. Antibody production is well known to those skilled in the arts (e.g., Dimitrov, A. S. 2009, Therapeutic antibodies: Methods and protocols, Humana Press; Dubel, S, (ed) 2010 Handbook of therapeutic antibodies: technologies, emerging developments and approved therapeutics, Wiley-Blackwell).
The protease inhibitors may be mixtures with the therapeutics, and be ionically coupled, or uncoupled to the therapeutic. Methods of preparing such mixtures are known to those skilled in the arts (Singh, M., (ed) 2007, Vaccine adjuvants and delivery systems, Wiley.
In a preferred embodiment, the inhibitor is covalently coupled to the therapeutic. Methods of covalently linking to therapeutic proteins are known to those skilled in the arts (e.g., Bioconjugate techniques, 2nd Ed. Greg T Hermanson Academic Press, Amsterdam, 2008; Bioconjugation Protocols; Strategies and Methods. Christof M. Niemeyer, (ed), Methods in Molecular Biology 283.Humana Press, Totowa, N.J., 2010;
In the production of therapeutic proteins, genetic constructs can be used to generate fusion proteins. The fusion proteins are generally produced as N-terminal or C-terminal fusions by the addition of DNA, in-frame, that codes for the fusion peptide. For example, the genes encoding monoclonal antibodies can be genetically engineered to be produced as peptide fusions, where the peptides are protease inhibitor peptides. The protease inhibitor peptides can be monomeric or polymeric, and may be activated through cleavage by the protease they inhibit or by other proteases. Methods of generating antibody protein fusions are well known to those skilled in the arts (e.g., Chamow, S. M and Ashkenazi, A. (eds) Antibody Fustion Proteins Wiley-Liss, New York; Kontermann, R. and Dubel, S. Antibody Engineering, Second Edition, 2010, Springer Verlag, Berlin; kreitman and Pastan, Making).
The protease inhibitors are those known inhibitors for proteases overexpressed in tumors, such as those from Table 2. A therapeutic antibody, such as Herceptin, is coupled to a polymeric protease-activated protease inhibitor. The polymeric protease inhibitor, such as a furin-activated furin inhibitor, in frame with the Herceptin antibody with the amino acid sequence (furin inhbitor IN CAPS; furin cleavage in lower case)
is genetically fused or covalently bound using methods known to those skilled in the arts (e.g., Bioconjugate techniques, 2nd Ed. Greg T Hermanson Academic Press, Amsterdam, 2008; Bioconjugation Protocols; Strategies and Methods. Christof M. Niemeyer, (ed), Methods in Molecular Biology 283.Humana Press, Totowa, N.J., 2010; Chamow, S. M and
Ashkenazi, A. (eds) Antibody Fustion Proteins Wiley-Liss, New York; Kontermann, R. and Dubel, S. Antibody Engineering, Second Edition, 2010, Springer Verlag, Berlin) to result in an antibody with a polymeric protease inhibitor as shown (
Number | Name | Date | Kind |
---|---|---|---|
20080286290 | Furusako et al. | Nov 2008 | A1 |
Entry |
---|
Laskowski, M., et al. 1980 Ann Rev Biochem 49: 593-626. |
Number | Date | Country | |
---|---|---|---|
61302763 | Feb 2010 | US |